Gastroenterologie up2date, Table of Contents Gastroenterologie up2date 2024; 20(04): 326-327DOI: 10.1055/a-2410-4180 Wichtige Studien im Fokus Kommentar zu: PPAR-Agonist bei primär biliärer Cholangitis wirksam Toni Herta , Frank Tacke Recommend Article Abstract Buy Article All articles of this category Comment on: PPAR-Agonist bei primär biliärer Cholangitis wirksamGastroenterologie up2date 2024; 20(04): 325-326DOI: 10.1055/a-2410-2844 Full Text References Literatur 1 Kowdley KV, Bowlus CL, Levy C. et al. Efficacy and Safety of Elafibranor in Primary Biliary Cholangitis. N Engl J Med 2024; 390: 795-805 2 Hirschfield GM, Bowlus CL, Mayo MJ. et al. A Phase 3 Trial of Seladelpar in Primary Biliary Cholangitis. N Engl J Med 2024; 390: 783-794 3 Corpechot C, Chazouillères O, Rousseau A. et al. A Placebo-Controlled Trial of Bezafibrate in Primary Biliary Cholangitis. N Engl J Med 2018; 378: 2171-2181 4 Corpechot C. The Role of Fibrates in Primary Biliary Cholangitis. Curr Hepatology Rep 2019; 18: 107-114 5 Perez CFM, Harns MH, Lindor KD. et al. Goals of treatment for improved survival in Primary Biliary Cholangitis: Treatment target should be bilirubin within the normal range and normalization of alkaline phosphatase. Am J Gastroenterol 2020; 115: 1066-1074
